April 24, 2025 - 23:22

Portal Bio has introduced an innovative microfluidic technology that promises to revolutionize drug discovery and cell engineering. This advanced solution enables efficient and scalable molecular delivery, particularly for sensitive cell types that have traditionally posed challenges in research and therapeutic applications.
With the ability to precisely manipulate small volumes of fluids, this technology facilitates the targeted delivery of compounds into cells, significantly enhancing the likelihood of successful outcomes in experiments. By streamlining the process, researchers can now explore a wider range of molecular interactions and cellular responses, paving the way for new discoveries in the field of biotechnology.
The implications of this technology extend beyond just improved efficiency; it also opens doors for the development of personalized medicine approaches. As scientists gain better control over how substances interact with cells, the potential for tailored therapies that cater to individual patient needs becomes increasingly viable. This advancement marks a significant step forward in the quest for more effective treatments and a deeper understanding of cellular behavior.
August 9, 2026 - 18:31
County agenda features tax, technology and fairgroundsThe meeting will center on how to fund the ongoing fairgrounds project, a long-discussed priority for the county. Officials are expected to review the latest cost estimates and possible revenue...
August 9, 2026 - 00:24
‘AI slop’ crackdown: LinkedIn, Snap target low-quality gen-AI contentSocial platforms are starting to push back against the flood of generic, machine-generated posts, but they are doing so carefully. LinkedIn and Snap have both announced new measures aimed at...
August 8, 2026 - 05:47
Why GigaCloud Technology (GCT) Is Up 21.7% After Strong Q2 Results And New Buyback PlanGigaCloud Technology saw its stock surge 21.7% in early trading following the release of its second-quarter financial results and the announcement of a new capital return program. The company...
August 7, 2026 - 22:40
As FDA Approves First-Ever mRNA Flu Vaccine For Older Adults, Past KFF Polling Showed Most In This Age Group Were Uncertain About the Technology’s SafetyOn August 5, 2026, the U.S. Food and Drug Administration gave the green light to the first messenger RNA flu vaccine for adults aged 50 and older. The decision came after a clinical trial involving...